Introduction
organelles, but when it is extensive, activated inappropriately or in cells which are unable to die by apoptosis, autophagy acts as an alternative cell-death pathway called programmed cell death type II
. Induction of autophagy by some anticancer agents such as tamoxyfen, rapamycin, arsenic trioxide, temozolomide, brevinin-2R or fullerenes appears to be deleterious for tumour cells [5] [6] [7] [8] [9] [10] [11] , thus indicating a possible use of autophagy as a 'magic bullet' in fighting apoptosis-resistant cancers [12] . On the other hand, a large body of evidence indicates that autophagy can also act as a survival mechanism that provides constituents necessary for sustaining essential cell metabolism in various stress conditions such as nutrient deprivation [13] . Moreover, inhibition of autophagy enhances the susceptibility of cancer cells to ionizing irradiation, hyperthermia, camptothecin, alkylating agents, hystone deacetylase inhibitors, sulindac sulphide and tumour necrosis factor-␣ [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . The intracellular changes consistent with the induction of autophagy were also observed in non-tumorigenic NIH/3T3 mouse fibroblast cell line treated with cisplatin [26] 
, suggesting that tumour cells in some conditions might employ autophagy as a mechanism to evade therapy-induced death. It has recently been shown that cisplatin-triggered autophagy partially protects primary renal tubular epithelial cells from concomitant induction of apoptotic cell death by the drug

, but the role of autophagy in cell survival/apoptosis was not investigated in this study. Moreover, the ability of cisplatin to trigger autophagic response in tumour cells has not been evaluated thus far, although the understanding of the role that autophagy might play in cisplatin-induced apoptosis could provide novel approaches to cancer treatment.
Adenosine monophosphate-activated protein kinase (AMPK), which acts as a principal intracellular energy sensor, has recently been implicated in the induction of autophagy [27] . AMPK is activated in various cellular and environmental stress conditions when AMP/ATP ratio is elevated and it generally acts by switching off ATP-requiring processes, while switching on ATP-generating catabolic pathways [28] . The mechanism by which AMPK activates autophagic response presumably involves downregulation of the kinase activity of mammalian target of rapamycin (mTOR) , which has been known as an important negative regulator of autophagy [29] . AMPK can either promote or inhibit cell death in a context-dependent and/or cell type-dependent manner [30] [31] [32] . A recent study described that the induction of AMPK in tumour cells exposed to cisplatin was cytoprotective [33] , but the possible involvement of AMPK in cisplatin-induced autophagy was not examined.
Development of tumour cell resistance to apoptosis induction is one of the major drawbacks in cisplatin therapy, and malignant gliomas are notorious for their ability to evade killing by conventional chemotherapeutics, including cisplatin [34] . In a search for novel approaches to increase cisplatin anticancer efficiency, we investigated the possible role of autophagy in cisplatin toxicity against U251 and C6 glioma cell lines, as well as the involvement of AMPK in cisplatin-induced autophagy in glioma cells. 
Materials and methods
Chemicals, cells and cell cultures
Assessment of cell death and apoptosis
ELISA
The cell-based ELISA was performed as previously described [36] 
Real-time RT-PCR analysis
Statistical analysis
The statistical significance of the differences between treatments was assessed using t-test or ANOVA followed by Student-Neuman-Keuls test for multiple comparisons. The value of P Ͻ 0.05 was considered significant.
Results
Cisplatin induces autophagy in tumour cells
Treatment with cisplatin for 16 hrs led to autophagy, as demonstrated by accumulation of acridine orange-stained red acidified
Fig. 1 Cisplatin-mediated induction of autophagy in tumour cells. (A, B) U251 glioma cells were incubated with cisplatin (cisPt 50 M, 16 hrs) with or without bafilomycin A1 (Baf 100 ng/ml) and stained with acridine orange. The presence of autophagic vesicles was assessed by fluorescent microscopy (A) or flow cytometry (B). (C-H) U251 (C, D, F, G), L929 (E, G, H) and C6 cells (E, G) were incubated with different concentrations (C) or 50 M (D-H) of cisplatin (cisPt) in the absence (C-H) or presence (F) of bafilomycin (Baf; 100 ng/ml) or wortmannin (Wm; 100 nm). Autophagy was analysed by flow cytometry after 16 hrs (C, E, F) or at the indicated time-points (D). Beclin-1 expression was determined at the indicated time-points by cell-based ELISA (G) or Western blotting (H). (I) TEM micrographs of control and cisplatin-treated (50 M, 16 hrs) C6 cells. The arrows show typical autophagosomes (left), some of which contained cytoplasmic organelles (right). Data are mean ϩ S.D. values from three independent experiments (C-F) or mean ϩ S.D. values of triplicate measurements from a representative of three experiments (G).
vesicles in the cytoplasm of U251 human glioma cells (Fig. 1A) . The accrual of acidic autophagolysosomes in cisplatin-treated cells was completely prevented by bafilomycin A1 (Fig. 1A) (Fig. 2C) , caspase activation (Fig. 2D ) and DNA fragmentation (Fig. 2E) Fig. 3A and C) , which resulted in the increase in Bax/Bcl-2 ratio at both mRNA (Fig. 3B ) and protein levels (Fig. 3D) . The autophagy inhibitor bafilomycin alone was apparently able to induce the expression of both Bax and Bcl-2 mRNA (Fig. 3A) , but the effect was somewhat less pronounced at the protein level (Fig. 3C ) and did not result in a significant disturbance of Bax/Bcl-2 ratio (Fig. 3B, D) . Nevertheless, bafilomycin further augmented cisplatin-induced alterations in Bax and Bcl-2 mRNA (Fig. 3A) and protein levels (Fig. 3C ) in U251 glioma cells, which was accordingly reflected in a significant increase in Bax/Bcl-2 ratio (Fig. 3B, D (Fig. 4D) . On the other hand, basal S6K phosphorylation was markedly lower in mTOR siRNAtransfected cells and only marginally reduced by cisplatin treatment (Fig. 4E) . Silencing of mTOR was sufficient to trigger beclin-1 up-regulation (Fig. 4F ) and autophagy in U251 cells (Fig. 4G) 
in U251 glioma cells, as demonstrated by flow cytometric analysis of the cells stained with the appropriate reporter fluorochromes that react with ROS (DHR), activated caspases (ApoStat) or DNA (PI). Each of the three autophagy inhibitors markedly
Fig. 2 The effects of autophagy inhibitors on cisplatin-induced apoptotic cell death. U251 cells (A-E), C6 or L929 cells (A) were incubated with cisplatin (cisPt; 50 M) in the absence or presence of bafilomycin (Baf; 100 ng/ml), wortmannin (Wm; 100 nm) or chloroquine (Cq; 20 M). LDH release (A), MTT reduction (B) and DNA fragmentation (E) were determined after 24 hrs, while ROS production (C) and caspase activation (D) were assessed after 16 hrs. (A, B) Data are mean ϩ S.D. values of triplicates from a representative of three experiments. (C, D, E) Representative flow cytometry histograms are presented, while the accompanying graphs contain mean ϩ S.D. values from three different experiments ( # P Ͻ 0.05 and *P Ͻ 0.05 refer to untreated and cisplatintreated cells, respectively). increased cisplatin-induced oxidative stress, caspase activation and DNA fragmentation (Fig. 3C-E), thus further corroborating that autophagy was involved in tumour cell protection from cisplatin-induced apoptosis. Similar results were obtained with C6 glioma and L929 fibrosarcoma cells (data not shown).
Autophagy inhibits Bax/Bcl-2 ratio increase in cisplatin-treated tumour cells
Since dysregulation of the balance between proapoptotic (Bax) and anti-apoptotic (Bcl-2) members of the Bcl-2 family of intracellular proteins can lead to caspase activation and apoptosis, we investigated the role of autophagy in modulating Bax/Bcl-2 ratio in cisplatin-exposed tumour cells. Consistent with its pro-apoptotic action, cisplatin increased expression of Bax while reducing that of Bcl-2 in U251 glioma cells (
AMPK and mTOR modulate survival of cisplatin-treated tumour cells
To further confirm the involvement of AMPK in cisplatin-induced autophagy, we tested whether siRNA-mediated AMPK silencing could mimic the stimulatory effect of autophagy inhibition on cisplatin toxicity. Indeed, siRNA-mediated down-regulation of AMPK activity in U251 cells augmented the cisplatin toxicity, as demonstrated by an increase in cisplatin-induced LDH release in AMPK siRNA-transfected, compared to control cell cultures (Fig. 5A) . Accordingly, AMPK silencing also mimicked bafilomycin-mediated increase in Bax/Bcl-2 mRNA ratio in cisplatin-treated U251 cells (Fig. 5B and C) . On the other hand, transfection with mTOR siRNA inhibited cisplatin-mediated tumour cell killing (Fig. 5A) , thus indicating that mTOR down-regulation might be involved in the cell protection by AMPK. The protective role of AMPK in cisplatinmediated tumour cell killing was confirmed by using compound C, an AMPK inhibitor, and metformin, an AMPK activator, which respectively enhanced and reduced cisplatin-triggered LDH release in C6, U251 and L929 cell cultures (Fig. 5D-F) .
Discussion
The presented data demonstrate the ability of cisplatin to initiate an autophagic response in different tumour cell lines, probably through AMPK/mTOR signalling pathway. Importantly, cisplatininduced autophagy protected tumour cells from the concomitant induction of apoptotic death. It should be noted that pharmacological inhibition of autophagy at different stages may exert different effects on cell death [8, 15] [4] . However, only two studies so far examined this possibility in cisplatin-treated cells [23, 24] . Both studies were performed on renal tubular epithelial cells, demonstrating that the inhibition of autophagy was accompanied by an increase in cisplatininduced caspase activation and subsequent nuclear fragmentation [23, 24] , which are principal events in apoptotic cell death [37] [49, 50] . An overproduction of ROS is also involved in transcriptional and post-transcriptional perturbation of Bax/Bcl-2 balance [51, 52] , which then leads to mitochondrial dysfunction and further increase in cell-damaging ROS production by mitochondria [53, 54] [55] , ischemic cardiac myocytes [56] and avicin D-treated cancer cells [57] . In some of these studies, AMPKdependent induction of autophagy was mediated by downstream inactivation of mTOR [56, 57] , a serine/threonine kinase that inhibits autophagy by blocking the expression of autophagyinducing Atg proteins and/or through direct interference with their function in autophagosome formation [58] . Pharmacological suppression of mTOR by rapamycin, as well as transfection with dominant-negative mTOR or mTOR siRNA, are sufficient for the induction of autophagy in cancer cells [7, 59] 
